

**Toowoomba
City**Today  7°/18°**The Chronicle**
We're for you

Hi, George

Today's
Paper

Toowoomba

World

Sport

Business

Opinion

Education

Health

Lifestyle

Entertainment

Puzzles ^{NEW}
**Business** [Stockhead](#)

ASX healthcare stocks riding the point-



Lumos and Atomo are making waves in point-of-care testing. Pic: Getty Images

Point-of-care testing emerges as one of the most disruptive shifts in global diagnostics



But long before Covid-19 POC testing was already bringing medical diagnostics out of laboratories and into GP clinics, pharmacies and homes leading to faster results and treatment.

The value proposition in oversold WA gold stocks
With gold coming back to life, small gold developers look oversold. Here's why Garimpeiro sees value in WA juniors Rumble and Javelin.



delivered.

Stockhead

Gold rush lifts ASX


CLIA waiver opens growth path for Lumos

Catalyst Metals led the small-cap charge with record Plutonic gold output while Pursuit

drilled into a major lithium brine target and Bounty surged on PEP11 appeal news

[Lumos Diagnostics \(ASX:LDX\)](#) flagship rapid point-of-care finger blood test

FebriDx is designed to differentiate between viral and bacterial respiratory



room rather than relying on overlapping symptoms."

Stockhead

Drone companies swarm on to the ASX

The test received US FDA 510(k) clearance in 2023, but Ward said the biggest

investors are spoilt for choice as companies focused on various aspects of drone technology swarm on to the ASX.

[Laboratory Improvement Amendments \(CLIA\) waiver.](#)

This allows FebriDx to be used in more than 300,000 waived testing sites across the US, including physician offices, urgent care centres and retail clinics.

Ward said FebriDx was the only CLIA-waived, instrument-free point-of-care test in the US that differentiated bacterial from non-bacterial respiratory infections across the full spectrum of respiratory illnesses rather than targeting a single virus.

"It's not just another rapid test," he said.



benem, McKesson, NDC and others, representing more than 2,000 trained Stockhead reps," Ward said.

Closing Bell: Goldies whoop it up as the ASX shines into the weekend

"Our own and PHASE's field teams are hyper-focused on the top 100 urgent care parent entities, which alone account for roughly half of all US urgent care sites, while partners like Henry Schein and McKesson cover the long tail



how the test fits into the workflow," Ward said. Stockhead

Gold miners bounce back After a minor waver, the uptick has not expanded to more than 40 sites and is now scaling across the broader Wall Street footprint in multiple states. Support and optimism an end to the Iran War is within sight.

Ward said FebriDx now had the regulatory clearance, clinical evidence, economic rationale and commercial infrastructure to become a standard POC tool for managing acute respiratory infections. Stockhead

Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. "The next respiratory season is about converting that foundation into visible, repeat repeat utilisation and revenue across a growing base of high-value accounts."

[Follow](#)

Beyond FebriDx, Lumos is also involved in a range of POC development programs through commercial and technical collaborations.



Lumos for their FebriDx test.

ASX Small Caps Weekly Form Guide

Atomo has an established presence in infectious disease testing, including HIV self-tests in markets such as Australia, New Zealand and the UK. Stockhead's end-of-week wrap covering small-cap ASX movers, news of note and expert recommendations – this week, from John Forwood.

It has also developed a rapid syphilis test, targeting a sexually transmitted infection (STI) that has re-emerged as a growing public health concern in

My News Feed

decline



testing at home.



SA News



Business

Blood spilt as chair,

Shift beyond POC testing to remote monitoring

iconic Aussie company

Mayfair Hotel to be

\$75m sale

Digital air traffic

for WFH, says

Airservices boss

While point-of-care testing continues to expand, Adherium (ASX:ADR) sits within a broader shift toward remote monitoring and decentralised healthcare.

Adherium's FDA-cleared UeLife SmartInhaler targets poor medication

adherence in respiratory medicine, which is a key driver of avoidable flare-ups, hospitalisations and declining disease control. **Good Morning George** Recommended based on what you've read

Chief commercial officer John Perry told *Stockhead* the device attached to standard asthma and COPD inhalers, automatically recording when medication was taken and capturing real-world usage data between clinical visits.

"Most adherence programs fail because they depend on the patient adopting a new habit," he said.

"Ours does not because capture is passive, so the data keeps flowing even from the older, disengaged, hard-to-reach patients who need it most.



changing clinical decisions.
QLD News



Cairns



SuperCoach

**Education department
worker on child abuse
charges loses pay
appeal**

He said it then became a matter of "coach or prescribe" where care teams could tell whether the fix was a technique correction or a medication change.

**Motorcyclist killed in
Bruce Highway crash
at El Arish**

**Late Mail: Dragon's
return stalls,
Crichton's finals swan
song alive**

And rather than adding another monitoring task for stretched clinicians, Adherium operates a managed care model where its team monitors adherence to therapy, engaged patients in their own care, and "provides a significant cases."

[Read More](#)

**What's On
Tennis
do in Toowoomba this
weekend**



**WATCH: Taylor Swift
arrives as A-listers roll
into NYC wedding chaos**



Adherium is also building a strong case for adoption, backed by clinical evidence from its iCARE program with Intermountain Health, based in Utah in the US, which has deployed 4,000 Hailie Smart inhalers across up to 2500

**Police hunt man who
Toowoomba thefts and
fraud**



**How old is Australian
television presenter Karl
Stevenson?**



"Patients on Hailie-connected controllers used them as prescribed two-thirds of the time, against the one-in-five typically reported in this population," Perry said.

**'Devastating': Top Aussie
suburbs facing negative
equity danger mapped**



**Fun as Aussies
\$61k govt fee 'for
nothing'**



The improvement translated into a 50.3% reduction in hospital admissions, a 20% reduction in emergency visits and a 57% fall in annual cost of care per patient, from US\$15,899. Patient engagement remained high, with retention above 90% at 12 months.

**Tributes for Brisbane
legend who put steak on
the map**



**Zac Efron visits surprise
Aus spot for dope
reason**



"The iCARE cost-of-care reductions are exactly what health system payers now buy under value-based reimbursement," he said.

"So this is not a pivot away from revenue. It is the path to larger, stickier, outcomes-linked revenue, and to Adherium becoming a digital respiratory care partner rather than a connected device company."

This story does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

At Stockhead we tell it like it is. While Lumos Diagnostics is a Stockhead advertiser, the company did not sponsor this article.

Originally published as [ASX healthcare stocks riding the point-of-care testing wave](#)

Membership	About Us	Contact Us	Our News Network	Our Partners	Our Apps
Group/Corporate Subscriptions	About Us	Help & support		Buy Search Sell Classifieds	
Today's Paper	Meet the Team	Story Tips	Courier Mail		
Newsletters	Job	FAQs	Herald Sun	Foxsports	
My Tributes	Opportunities	Standards of practice	The Daily Telegraph	Hipages	
	Code of Conduct	Letter to the Editor	The Advertiser	Kayo	
	Subscription FAQs		news.com.au	My Tributes	
	Subscription terms	Licensing & Reprints	Gold Coast Bulletin	Punters	
	Financial Hardship Policy	Advertise with us	The Cairns Post	odds.com.au	
			Townsville Bulletin	racenet.com.au	
			NT News	Sky News	
			The Mercury	Coupons	
			Geelong Advertiser		
			The Weekly Times		
			CODE Sports		

A NOTE ABOUT RELEVANT CONTENT: We collect information about the content (including ads) you use across this site and use it to make both advertising and content more relevant to you on our network and other sites. Find out more about our policy and your choices, including how to opt-out of targeted advertising based on your browsing behaviour on our network. Sometimes our articles will try to help you find the right product at the right price. We may receive payment from third parties for publishing this content or when you make a purchase through the links on our sites.

Nationwide News Pty Ltd © 2026. All times AEST (GMT +10). Powered by WordPress.com VIP

[Privacy policy](#) [Relevant ads opt-out](#) [Cookie policy](#) [Terms of use](#)